Brought to you by 
Eloxx brings in first $5mm of $24mm Series C
10 Mar 2023
Executive Summary
Israeli biotech Eloxx Pharmaceuticals Ltd. (focused on genetic diseases caused by nonsense mutations) raised $5mm from Quark Venture and GF Securities (through their Global Health Science Fund) as the first part of a potential $24mm Series C round led by Pontifax.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Technologies
- Large Molecule
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eloxx brings in first $5mm of $24mm Series C
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice